Grief, Cannabis, and Care Gaps: Family Campaign Calls for Stricter Medical Cannabis Safeguards in Mental Health Cases!

April 6, 2026 5 Min Read

Reported by Musa Antiketu, | Journalist at Sele Media Africa.

A growing debate around the regulation of medical cannabis has resurfaced following a deeply personal campaign launched by the brother of a man who died by suicide while undergoing treatment involving prescribed cannabis. The case has reignited scrutiny over patient safety, prescribing practices, and regulatory oversight particularly for individuals with complex mental health conditions.
At the heart of the campaign is a call for tighter controls on access to medical cannabis for patients with histories of severe psychiatric disorders. The bereaved family argues that current frameworks may not adequately protect vulnerable individuals, especially those experiencing conditions such as depression, anxiety, or psychosis.
A Personal Tragedy Spurs Public Advocacy
The campaign emerged after the man whose identity has been widely reported in British media died while reportedly using legally prescribed cannabis products for therapeutic purposes. His brother has since become an outspoken advocate for reform, insisting that the system failed to account for the risks associated with cannabis use in patients with pre-existing mental health conditions.
According to the family, the deceased had a documented history of psychological distress prior to being granted access to medical cannabis. They allege that insufficient safeguards and a lack of coordinated mental health monitoring contributed to a deterioration in his condition.
This is not about demonising medical cannabis, the brother stated in interviews. It’s about ensuring that people who are already vulnerable are not exposed to treatments that could worsen their mental health without proper oversight.
The Expanding Landscape of Medical Cannabis
Medical cannabis has gained increasing acceptance across parts of Europe, North America, and other regions, with regulators approving its use for conditions ranging from chronic pain and epilepsy to multiple sclerosis. In the United Kingdom, cannabis-based medicinal products were legalised for specialist prescription in 2018, marking a significant shift in healthcare policy.
However, access remains tightly controlled, often requiring private prescriptions due to limitations within public healthcare systems. This has led to the emergence of a rapidly expanding private sector, where clinics provide cannabis-based treatments to patients who may not qualify under stricter public guidelines.
Critics argue that this growth has outpaced regulatory safeguards, creating inconsistencies in patient screening, follow up care, and risk assessment particularly for individuals with psychiatric vulnerabilities.
Mental Health Risks Under Scrutiny
Scientific research on cannabis and mental health presents a complex picture. While some patients report relief from anxiety and insomnia, others may experience exacerbated symptoms, including paranoia, mood instability, or psychotic episodes especially when exposed to high THC products.
Mental health experts have long cautioned against the use of cannabis in individuals with a history of severe psychiatric illness. Studies have suggested a potential link between cannabis use and increased risk of psychosis, particularly among younger individuals or those genetically predisposed.
The recent case has amplified concerns that existing prescribing frameworks may not sufficiently differentiate between patients who could benefit from cannabis-based treatments and those for whom the risks outweigh potential gains.
Regulatory Gaps and Industry Pressures
The bereaved family’s campaign highlights what they describe as systemic gaps in regulation. Among their key demands are:
Stricter eligibility criteria for patients with documented mental health conditions
Mandatory psychiatric evaluations prior to prescribing cannabis based products
Improved monitoring and follow up protocols for at-risk patients
Greater transparency in private cannabis clinics’ prescribing practices
Healthcare analysts note that the private nature of many medical cannabis services can complicate oversight. Unlike public health systems, where treatment pathways are often standardised, private providers may operate with varying levels of scrutiny.
There are also concerns about commercial pressures within the industry. As demand for medical cannabis grows, some critics argue that financial incentives could influence prescribing patterns, potentially leading to over-prescription or inadequate patient assessment.
Calls for Balanced Reform
While the campaign has gained traction, it has also sparked debate among patient advocacy groups and medical professionals who caution against overly restrictive measures.
Supporters of medical cannabis emphasise its therapeutic benefits for many patients, particularly those who have not responded to conventional treatments. They argue that tightening access too aggressively could deprive individuals of a potentially life-improving option.
Instead, some experts advocate for a balanced approach one that strengthens safeguards without undermining legitimate medical use. This includes investing in research, improving clinician training, and establishing clearer guidelines for mental health screening.
Broader Implications for Global Health Policy
The case resonates beyond the United Kingdom, reflecting broader challenges faced by countries navigating the integration of cannabis into medical practice. Across Africa, where discussions around cannabis legalisation are gaining momentum, the issue underscores the importance of robust regulatory frameworks.
Countries such as South Africa, Lesotho, and Zimbabwe have already taken steps toward legalising cannabis for medical or commercial purposes. However, mental health infrastructure in many African nations remains underdeveloped, raising concerns about the capacity to manage potential risks associated with cannabis use.
Public health experts suggest that African policymakers can draw lessons from international experiences, ensuring that mental health considerations are embedded in cannabis legislation from the outset.
Media Coverage and Public Reaction
The story has been widely covered by reputable international media outlets, including the BBC, The Guardian, and Sky News, each highlighting the family’s call for reform and the broader implications for patient safety.
Public reaction has been mixed. While many sympathise with the family’s loss and support calls for stronger safeguards, others warn against attributing causality too simplistically. Mental health crises are often multifaceted, involving a combination of biological, psychological, and social factors.
Nevertheless, the case has succeeded in prompting a critical conversation about the intersection of mental health and emerging medical treatments.
The Need for Evidence Based Policy
At its core, the debate underscores the importance of evidence-based policymaking. As medical cannabis continues to gain acceptance, regulators face the challenge of balancing innovation with patient safety.
This requires ongoing research into the effects of cannabis on different patient populations, particularly those with mental health conditions. It also demands collaboration between clinicians, researchers, policymakers, and patient advocates to develop guidelines that are both rigorous and adaptable.
A Family’s Quest for Change
For the bereaved brother, the campaign is ultimately about preventing similar tragedies. By sharing his family’s experience, he hopes to shine a light on what he sees as preventable risks within the current system.
“Our goal is not to stop people from accessing treatment,” he said. It’s to make sure that treatment is safe, responsible, and appropriate for each individual.
As the conversation continues, his advocacy has added a human dimension to a complex policy issue reminding stakeholders that behind every regulation are lives profoundly affected by the decisions made.